CD4 and Alzheimer disease: When we inadvertently found the effect of the anti-CD4 antibody while investigating the effect of aducanumab [29] and encountered the probable effect of allogeneic natural killer (NK) cell supplements in AD models [30], we questioned which cells or transcriptomic markers in the brain areas would be the best to predict the outcome of these novel, currently unaccounted therapeutic candidates.